Abstract
The cyclin dependent kinases, Cdks, are potential targets for new anticancer therapy. Dysregulation of the cell cycle is common during tumorigenesis, and inhibition of certain Cdks has been shown to inhibit tumor cell growth, induce apoptosis and cause tumor regressions in animal models. This review discusses the rationale for inhibiting Cdks as an approach to cancer therapy and the status of Cdk inhibitors in clinical trials. Compounds resulting from a patent literature search from 2003 to July, 2005 are discussed.
Keywords: Cyclin dependent kinases, cell cycle, BMS-387032, flavopridol, roscovitine, UCN-01, tumorigenesis, apoptosis, anticancer agents, Cdk1
Recent Patents on Anti-Cancer Drug Discovery
Title: Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature
Volume: 1 Issue: 3
Author(s): Andrea D. Basso and Ronald J. Doll
Affiliation:
Keywords: Cyclin dependent kinases, cell cycle, BMS-387032, flavopridol, roscovitine, UCN-01, tumorigenesis, apoptosis, anticancer agents, Cdk1
Abstract: The cyclin dependent kinases, Cdks, are potential targets for new anticancer therapy. Dysregulation of the cell cycle is common during tumorigenesis, and inhibition of certain Cdks has been shown to inhibit tumor cell growth, induce apoptosis and cause tumor regressions in animal models. This review discusses the rationale for inhibiting Cdks as an approach to cancer therapy and the status of Cdk inhibitors in clinical trials. Compounds resulting from a patent literature search from 2003 to July, 2005 are discussed.
Export Options
About this article
Cite this article as:
Basso D. Andrea and Doll J. Ronald, Inhibition of Cyclin-Dependent Kinases - A Review of the Recent Patent Literature, Recent Patents on Anti-Cancer Drug Discovery 2006; 1 (3) . https://dx.doi.org/10.2174/157489206778776916
DOI https://dx.doi.org/10.2174/157489206778776916 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Gene Therapy for Gastric Diseases
Current Gene Therapy Arene ruthenium(II) Complexes: The Promising Chemotherapeutic Agent in Inhibiting the Proliferation, Migration and Invasion
Mini-Reviews in Medicinal Chemistry The Role of Apoptosis in Tumor Progression and Metastasis
Current Molecular Medicine A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design Understanding the Molecular Mechanisms of Betel miRNAs on Human Health
MicroRNA Dietary Antioxidants as Potential Pharmacological Agents for Ischemic Stroke
Current Medicinal Chemistry Analytical Techniques for DNA Methylation – An Overview
Current Pharmaceutical Analysis B7-H3 Immune Checkpoint Protein in Human Cancer
Current Medicinal Chemistry Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series
Current Drug Therapy LncRNA HOTAIR Polymorphisms Association with Cancer Susceptibility in Different Tumor Types
Current Drug Targets Can Dietary Antioxidants Reduce the Incidence of Brain Tumors?
Current Drug Metabolism The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals HER2-Mediated Anticancer Drug Delivery: Strategies to Prepare Targeting Ligands Highly Specific for the Receptor
Current Medicinal Chemistry Physiologically Based Pharmacokinetic Models: Integration of In Silico Approaches with Micro Cell Culture Analogues
Current Drug Metabolism Innovative Cancer Treatments that Augment Radiotherapy or Chemotherapy by the Use of Immunotherapy or Gene Therapy
Recent Patents on Anti-Cancer Drug Discovery